Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal
cancers, with a 5-year survival rate of less than 5%. In fact, complete surgical resection …

Background Diagnosis of pancreatic ductal adenocarcinoma (PDAC) is difficult due to the
lack of specific symptoms and screening methods. Only less than 10% of PDAC patients are …

Pancreatic ductal adenocarcinoma is one of the most lethal tumors since it is usually
detected at an advanced stage in which surgery and/or current chemotherapy have limited …

Simple Summary A highly desirable approach to diagnose a human disease quickly and
easily is to identify a chemical, protein, or antibody in a biofluid like blood or urine that is …

Background Early detection of pancreatic ductal adenocarcinoma (PDAC) may improve the
prognosis of patients. This study was to identify metabolic features of PDAC and to discover …

Pancreatic cancer (PC) is the fourth leading cause of cancer death in the United States, with
4% survival, 5 years after diagnosis. Patients with pancreatic cancer are usually diagnosed …

Pancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is
no blood test for early detection and diagnosis of this disease. Several research groups …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year
survival rates around 10%. The only curative option remains complete surgical resection, but …

Metabolomics is a rapidly growing field of research used in the identification and
quantification of the small molecule metabolites within an organism, thereby providing …

Background Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of
cancer deaths worldwide with less than a 6% 5-year survival rate. PDAC is associated with …